• Skip to main content
  • Skip to footer

PeDRA

Pediatric Dermatology Research Alliance

  • DONATE
  • Join PeDRA
  • Login
MENUMENU
  • Contact Us
  • For Patients & Families
        • Patient Support
        • Patient Education
        • Community Spotlight
        • Play Eczema Counts Now!
        • Patient Advisory Committee
        • Find a Pediatric Dermatologist (from SPD)
        • Awards Program
        • Parents, advocates, and patients over the age of 18 with a direct connection or significant interest in childhood skin disease or pediatric dermatology research are encouraged to join the PeDRA network for free as Community Members.

          Apply Now!

  • Education and Events
        • Virtual Education
        • SPD/PeDRA Journal Club
        • PeDRA Pearls Podcast
        • Mentorship Program
        • 2023 Annual Conference
        • 2023 Dash for Discovery Fun Run/Walk
        • Early Investigator Support
        • Play Eczema Counts Now!
        • Events Calendar
        • Explore our educational catalog!

  • Research
        • Grants and Fellowships
        • Resources for Researchers
        • Survey Application
        • Study Application
        • Research Areas
        • Publications
        • PeDRA EDI Corner
        • View all open funding opportunities!

  • Membership
        • New to PeDRA? Apply Here
        • 2024 Membership Renewal
        • Member Dashboard
  • About
        • Mission, Vision, and Core Values
        • Leadership & Staff
        • Annual Reports & Financials
        • Awards Program
        • News Archive
        • Our Supporters
        • Our Membership
        • Member Spotlight
        • Our Committees
        • Getting to Know You
        • It’s Membership Renewal Time – Renew today!

  • Member Login

T regulatory cell dysfunction and Staphylococcus aureus infection enable atopic dermatitis onset and progression

January 12, 2023 By Katherine Devenport

Principal Investigator:

Hazel Wilkie, PhD
Boston Children’s Hospital

Overview:

Atopic dermatitis (AD, also called allergic eczema) affects 20% of children and 10% of adults. The dry, red, itchy skin lesions are often infected with bacteria. Intriguingly, skin bacterial burden increases prior to the development of eczema lesions in infant children but how or if the bacteria is causing the disease is not clear.

AD often occurs in children whose parents also suffer from allergies. This heritable link is associated with mutations in numerous genes. Patients with mutations in the DOCK8 gene universally suffer from severe AD and bacterial infections. Mice with the same DOCK8 mutations as the patients are an excellent model to investigate the pathways underlying the development of AD. We will test novel treatment strategies that target these pathways in order to reduce allergic skin inflammation.

This work will illuminate novel therapies for eczema patients targeted towards preventing disease and restoring suppression of allergic skin inflammation.

Status:

This project was funded by a 2022 PeDRA Research Grant.

Filed Under: Active Studies, AD&PsO Ongoing, Atopic Derm & Psoriasis

Footer

  • Our Membership
  • For Patients
  • For Researchers
  • Governance Policies
  • Financial Conflict of Interest Policy
  • Jobs at PeDRA
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sign up to receive emails from PeDRA

Four Star Charity Navigator

Join PeDRA
Donate

Copyright © 2023 · Pediatric Dermatology Research Alliance (PeDRA) · All Rights Reserved. · Privacy Policy